Evidence map›Paper›PMID 35509962›Full record

ReviewClinicoEconomics and outcomes research : CEOR2022

Economic Burden of COVID-19: A Systematic Review.

Fayolah Richards, Petya Kodjamanova, Xue Chen, Nicole Li, Petar Atanasov, Liga Bennetts, Brandon J Patterson, Behin Yektashenas, Marco Mesa-Frias, Krzysztof Tronczynski and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ClinicoEconomics and outcomes research : CEOR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fayolah RichardsJanssen Global Services, Raritan, NJ, USA.
Petya KodjamanovaHEMA Amaris, Sofia, Bulgaria.
Xue ChenHEMA Amaris, Shanghai, People's Republic of China.
Nicole LiHEMA Amaris, Toronto, Canada.
Petar AtanasovHEMA Amaris, Barcelona, Spain.ORCID 0000-0001-5439-5296
Liga BennettsHEMA Amaris, Montréal, Canada.
Brandon J PattersonJanssen Global Services, Raritan, NJ, USA.
Behin YektashenasJanssen Global Services, Raritan, NJ, USA.
Marco Mesa-FriasJanssen Scientific Affairs LLC, Titusville, NJ, USA.ORCID 0000-0002-2880-8373
Krzysztof TronczynskiEMEA Janssen, Warsaw, Poland.
Nasuh BuyukkaramikliR&D Janssen, Beerse, Belgium.
Antoine C El KhouryJanssen Global Services, Raritan, NJ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To review and qualitatively synthesize the evidence related to the economic burden of COVID-19, including healthcare resource utilization and costs. Methods: A systematic review of studies that assessed the economic burden [eg, direct costs, productivity, macroeconomic impact due to non-pharmaceutical interventions (NPIs) and equity] of COVID-19 was conducted by searches in EMBASE, MEDLINE, MEDLINE-IN-PROCESS, and The Cochrane Library, as well as manual searches of unpublished research for the period between January 2020 to February 2021. Single reviewer data extraction was confirmed independently by a second reviewer. Results: The screening process resulted in a total of 27 studies: 25 individual publications, and 2 systematic literature reviews, of narrower scopes, that fulfilled the inclusion criteria. The patients diagnosed with more severe COVID-19 were associated with higher costs. The main drivers for higher costs were consistent across countries and included ICU admission, in-hospital resource use such as mechanical ventilation, which lead to increase costs of $2082.65 ± 345.04 to $2990.76 ± 545.98. The most frequently reported indirect costs were due to productivity losses. On average, older COVID-19 patients incurred higher costs when compared to younger age groups. An estimation of a 20% COVID-19 infection rate based on a Monte Carlo simulation in the United States led to a total direct medical cost of $163.4 billion over the course of the pandemic. Conclusion: The COVID-19 pandemic has generated a considerable economic burden on patients and the general population. Preventative measures such as NPIs only have partial success in lowering the economic costs of the pandemic. Implementing additional preventative measures such as large-scale vaccination is vital in reducing direct and indirect medical costs, decreased productivity, and GDP losses.

Indexed as

costscovid-19economic Impacthealth Economicssymptom Burdenvaccines

Identifiers

PMID35509962
PMCPMC9060810

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.